The CYP2C19 681 G > A mutation, which is associated with reduced clopidogrel antiplatelet activity, is an important marker for poor prognosis in ACS patients receiving clopidogrel treatment.[24] Moreover, a recent meta-analysis, carried out on nearly 8000 patients with CAD undergoing clopidogrel treatment, showed that the CYP2C19∗2 polymorphism is associated with an increased risk of major adverse cardiovascular events and stent thrombosis.[25] However, little has been reported about the relationship between P2RY12 gene polymorphisms and the risks of adverse CVD events after PCI. Here, CYP2C19 is linked to coronary artery disorder.